Locus Cell Co., Ltd.
TWO: 6891.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Yu Hsiang Chang
- Employees
- 53
- Headquarters
- New Taipei City, Taiwan
- IPO year
- 2022
- Market cap
- NT$11.2B
- Website
- https://www.locuscell.com
Loading 6891…
Loading profile data…Frequently asked questions about 6891
What does Locus Cell Co., Ltd. (6891.TWO) do?
The company operates in biotechnology / cell therapy: contract development and manufacturing (CDMO) of cells (e.g. adipose-derived stem cells, nerve cells, chondrocytes, fibroblasts, 3D printing of cell products, and regenerative medical product CDMO like CAR-T, MSC, iPSC)
Where does 6891.TWO trade?
Locus Cell Co., Ltd. (6891.TWO) trades on the Taipei Exchange.
What sector is 6891.TWO in?
Locus Cell Co., Ltd. (6891.TWO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Locus Cell Co., Ltd.?
Yu Hsiang Chang is the chief executive officer of Locus Cell Co., Ltd. (6891.TWO).
Where is Locus Cell Co., Ltd. headquartered?
Locus Cell Co., Ltd. is headquartered in Taiwan.
Does 6891.TWO pay a dividend?
Locus Cell Co., Ltd. (6891.TWO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 6891.TWO go public?
Locus Cell Co., Ltd. (6891.TWO) completed its initial public offering in 2022.